A Study of a FimH Blocker, EB8018, in Crohn's Disease Patients

• Status: Completed
• Trial end date: 2019-12-04
• Target enrollment: 0
• Participant gender: All

Summary

Enterome small molecule drug EB8018 is a first-in-class FimH blocker to be studied in Crohn's disease patients. The proposed indication for EB8018, as an add-on therapy, will be the treatment of adult patients suffering from Crohn's disease.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Enterome

Criteria

Selection Criteria:

• Male and female patients of nonchildbearing potential ≥18 years of age at screening and Day -1

• Active Crohn's disease based on an elevated calprotectin at baseline.